Mavyret 20 mg/1 (Glecaprevir and Pibrentasvir PELLET) 20 mg/1

Mavyret is a combination medication containing glecaprevir and pibrentasvir, used for treating certain types of hepatitis C. This oral pellet formulation is designed for convenient administration.

Strength

20 mg/1

Pack Size

1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mavyret is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It is effective for various genotypes of HCV, offering a comprehensive solution for managing this condition. Patients often wonder, 'What is Mavyret used for?' and the answer lies in its ability to target and inhibit the virus, aiding in its eradication.

Side Effects

Common effects of Mavyret may include fatigue, headache, and nausea. Some individuals might experience changes in their bowel movements or mild gastrointestinal discomfort. These effects are generally temporary and vary among users.

Precautions & Warnings

Mavyret should be handled with care, ensuring it is stored properly to maintain its efficacy. It is important to follow the guidance of a healthcare provider regarding its use, especially for those with pre-existing liver conditions or other health concerns.

Avoid Interactions

Mavyret may interact with certain medications, including those metabolized by the liver. It is advisable to consult a healthcare provider before combining Mavyret with other treatments, particularly those that affect liver function or are known to interact with antiviral drugs.

References

Frequently Asked Questions

Mavyret is used for the treatment of chronic hepatitis C virus (HCV) infection, targeting various genotypes of the virus.

Mavyret is administered orally in pellet form, typically once daily. Follow the instructions provided by your healthcare provider.

Common side effects may include fatigue, headache, nausea, and mild gastrointestinal discomfort.

Mavyret may interact with certain medications, so it is important to consult a healthcare provider before combining it with other treatments.

Mavyret is effective for various genotypes of hepatitis C, but its suitability depends on individual health conditions and should be determined by a healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.